SMMT — Summit Therapeutics Share News
0.000.00%
Last trade - 00:00- $12.26bn
- $11.57bn
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination
UK Stocks-Factors to watch on October 2 (updated)
Brief: AstraZeneca & Daiichi Sankyo announce clinical collaboration with Summit Therapeutics
Factbox: Major drugmakers turn to China for licensing deals
Summit soars after $2 billion investment from AstraZeneca for cancer therapies
US RESEARCH ROUNDUP-Acuity, Dell Technologies, Nike
AstraZeneca rises after $2 billion equity investment in Summit Therapeutics
HK's Akeso rallies after AstraZeneca invests $2 billion in Summit, backs ivonescimab
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up
Summit surges after AstraZeneca makes $2 billion equity investment
Factbox: US drugmakers turn to China for licensing deals
U.S. STOCKS ON THE MOVE-Apple, Omnicom, Jersey Mike's Subs